DR. HETTY ANNE WASKIN, M.D.
Osteopathic Medicine at Galloping Hill Rd, Kenilworth, NJ
License number
New Jersey 25MA07346700
Category
Osteopathic Medicine
Type
Infectious Disease
License number
New Jersey 32296
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
2
2015 Galloping Hill Rd, Kenilworth, NJ 07033
40 Muentener Dr, Montgomery, NJ 08558
40 Muentener Dr, Montgomery, NJ 08558
Phone
(908) 740-2364
(908) 425-3071
(908) 425-3071
Professional information
Dr. Hetty A Waskin, Kenilworth NJ - MD (Doctor of Medicine)
Specialties:
Infectious Disease Medicine
Address:
2015 Galloping Hill Rd, Kenilworth 07033
(908) 740-2364 (Phone)
(908) 740-2364 (Phone)
Certifications:
Infectious Disease, 1988, Internal Medicine, 1981
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Mi Med Sch
Graduated: 1978
Rush-Presby-St Lukes Med Ct
U Nm Sch Med
University of Mi Med Sch
Graduated: 1978
Rush-Presby-St Lukes Med Ct
U Nm Sch Med
High Density Compositions Containing Posaconazole And Formulations Comprising The Same
US Patent:
2011012, May 26, 2011
Filed:
Apr 15, 2009
Appl. No.:
12/999547
Inventors:
Larry Yun Fang - Plainsboro NJ, US
David Harris - New Providence NJ, US
Gopal Krishna - North Brunswick NJ, US
Russell C. Prestipino - Hoboken NJ, US
Marc Steinman - Livingston NJ, US
Jiansheng Wan - Warren NJ, US
Hetty Anne Waskin - Skillman NJ, US
David Harris - New Providence NJ, US
Gopal Krishna - North Brunswick NJ, US
Russell C. Prestipino - Hoboken NJ, US
Marc Steinman - Livingston NJ, US
Jiansheng Wan - Warren NJ, US
Hetty Anne Waskin - Skillman NJ, US
International Classification:
A61K 31/496, A61K 9/14, A61P 31/10
US Classification:
424489, 51425407
Abstract:
The present application provides novel compositions comprising posaconazole and a polymer wherein the composition has a glass transition temperature (Tg) of less than about 1100 C. The application also describes compositions comprising posaconazole and a polymer having a bulk density of greater than about 0.4 mg/mL. The application also describes compositions comprising posaconazole and a polymer which provide an exposure (AUCtf) of at least about 10,000 ng·hr/mL when administered to a patient in a fasted state. The application also describes a novel process for preparing these compositions. The preff erred polymer is HPMCAS. Preferably the composition is an extruded material.